Navigation Links
Spherix Shareholders Support Company's Focus on Naturlose, Biotechnology
Date:8/19/2007

Changes Approved for Board of Directors and Corporate Officers

BELTSVILLE, Md., Aug. 16 /PRNewswire-FirstCall/ -- Shareholders of Spherix Incorporated (Nasdaq: SPEX) voted to approve the sale of the Company's InfoSpherix subsidiary to The Active Network for $17 million in cash ($15 million at closing and $2 million following a 15-month escrow period). The vote was formally recorded at the Company's annual meeting at its headquarters in Beltsville, Maryland.

At the annual meeting, shareholders elected the following members to the Board of Directors:

-- Douglas T. Brown, Senior Vice President and Manager of the Corporate

Banking Government Contracting Group for PNC Bank

-- A. Paul Cox, Jr., Principal, Asset Protection Company

-- George C. Creel, former Executive VP and Chief Operating Officer,

Baltimore Gas and Electric Co.

-- Gilbert V. Levin, Ph.D., Spherix

-- M. Karen Levin, former VP for Spherix

-- Richard C. Levin, Spherix

-- Robert A. Lodder, Jr., Director of the Analytical Spectroscopy Research

Group of the Advanced Science and Technology Center at the University

of Kentucky

-- Robert J. Vander Zanden, Ph.D., former Vice President, R&D, Kraft Foods

International

In addition, Grant Thornton LLP was selected as the Company's independent accountants for the year 2007.

Richard Levin told shareholders that the phase 3 clinical trial for Naturlose as a diabetes treatment was going well and the entire study will now be conducted in the United States. The trial is scheduled to finish in early- to mid-2009, he said, noting, "Patient recruitment is going smoothly, patients have been on the drug for months now, and none have withdrawn. This is a very encouraging sign."

Levin said that the Company's primary goal is to interest a pharmaceutical partner in Naturlose. To that end he said, while the phase 3 trial is running, Spherix will put together a data package geared for the pharmaceutical industry. Levin said, "Perhaps most importantly, we will begin to develop the market. This includes educating potential users on the product and its benefits, and determining the best path to market."

Levin said that the Company is finalizing the protocol for a dose range study. An additional arm to the study will determine if Naturlose will work with one dose per day. Levin concluded his comments by saying, "I believe the biotech side of the company is positioned well for success. It will have a substantial cash reserve, an exciting product in a phase 3 clinical trial, and a solid leader in Dr. Claire Kruger. We could not have found a better person to lead us through this phase in the Company's history."

At a Board of Directors meeting later the same day, the Board elected Claire Kruger, Ph.D., as CEO of Spherix to replace Richard Levin, who will continue to manage InfoSpherix, becoming an employee of The Active Network. Dr. Kruger will also be responsible for building Spherix's new business line in health sciences consulting. Board member Robert Lodder, Ph.D., was elected President of Spherix.

In addition, the Board of Directors nominated Paul Cox as Chairman, and the following slate of Corporate Officers was elected:

-- Paul Cox, Chairman of the Board

-- Claire Kruger, CEO/COO

-- Robert Lodder, President

-- Katherine Brailer, Corporate Secretary and Director of Administrative

Services

-- Robert Clayton, Interim CFO and Treasurer

At this meeting, Gilbert Levin, Ph.D., was made Chairman Emeritus. In order to satisfy Sarbanes-Oxley regulations that the majority of the Board must be independent, Richard Levin and Karen Levin resigned from the Spherix Board of Directors, and Claire Kruger was elected as a Member.

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on March 3, 1999.

Under its motto, "A World of Solutions," Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in information technology, knowledge management, and biotechnology.

Spherix's Internet address is http://www.spherix.com .


'/>"/>
SOURCE Spherix Incorporated

Copyright©2007 PR Newswire.

Related biology technology :

1. QIAGEN Instrument Service insist on the best in service and support
2. QIAGEN Instrument Service - insist on the best in service and support
3. Doyle urges Legislature to support biofuels program
4. CDW buyer supports Berbee growth plans
5. Doyle urges support of higher education spending
6. Doyle joins governors in support of stem cell bill
7. Wisconsin firms pledge to support healthcare IT standards
8. Rockwells $1M gift to UWM will support advanced automation research
9. MATC bio-diesel reactor to support training
10. Computer recycling: An environmental mandate the private sector can support
11. Net neutrality will be back, supporters vow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree ... products targeting the needs of consumers who are incorporating medical marijuana into their ... Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C ... software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October 24th, ABC² ... the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will be ... and open to the public, but registration is required. , WHAT: ABC² ...
Breaking Biology Technology:
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
Breaking Biology News(10 mins):